Difference between revisions of "Ankyrin"
m |
m |
||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 45: | Line 45: | ||
| | | | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] |
Latest revision as of 11:24, 10 March 2015
Ankyrin | |
---|---|
Substrate peptide name | Ankyrin |
Synonyms | - |
Determination type | In situ/In vitro |
Source | Homo sapiens |
Subcellular localization | Erythrocyte cytoskeleton |
Swissprot ID | P16157 |
Reactive glutamines | Not determined yet |
Reactive lysines | Not determined yet |
Substrate sequence | |
Structure | 1N11 |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:2881577 |
Notes | |